Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib

Alectinib is approved and recommended as the preferred first‐line treatment for patients with anaplastic lymphoma kinase (ALK)‐positive non–small cell lung cancer. The effect of hepatic impairment on the pharmacokinetics (PK) of alectinib was assessed with physiologically based PK modeling prospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Morcos, Peter N., Cleary, Yumi, Sturm‐Pellanda, Carolina, Guerini, Elena, Abt, Markus, Donzelli, Massimiliano, Vazvaei, Faye, Balas, Bogdana, Parrott, Neil, Yu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282775/
https://www.ncbi.nlm.nih.gov/pubmed/30052269
http://dx.doi.org/10.1002/jcph.1286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282775/
https://www.ncbi.nlm.nih.gov/pubmed/30052269
http://dx.doi.org/10.1002/jcph.1286

Ejemplares similares